We have won more than $40 billion in jury verdicts and settlements and have been in business for almost 70 years.
Levin Papantonio continues to actively participate in litigating cases involving atypical femur fractures in long-term bisphosphonate users. The term “atypical femur fracture” is used to describe a fracture of either the mid-shaft or subtrochanteric regions of the femur. There is a growing body of medical literature linking these fractures to the long-term use of bisphosphonates such as Fosamax, Actonel, and Boniva.
The vast majority of the filed cases nationwide are located in New Jersey Superior Court in Atlantic County. The first Bellwether trial in this litigation is tentatively scheduled to commence in late 2012. As always, we are on the front lines of this litigation and expect to be actively involved in upcoming trials. Both Timothy O’Brien and Brandon Bogle at our firm are intimately familiar with the science surrounding atypical femur fractures and the liability case against the bisphosphonate manufacturers for the defects in their products which cause these catastrophic injuries. For more information on these cases contact Tim O’Brien at tobrien@levinlaw.com or Brandon Bogle at bbogle@levinlaw.com
Fosamax Lawsuit
Levin Law